In vitro activity of tigecycline as a therapeutic option against multidrug-resistant Acinetobacter spp.

New Microbiologica

Volumn 31, Issue 4, 2008, Pages 535-542

  Eser, Özgen Köseoǧlu ^a,b   Ergin, Alper ^b   Tunçkanat, Ferda ^a   Hasçelik, Gülşen ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Acinetobacter; Glycylcycline; Metallo beta lactamases; Multidrug resistance

Indexed keywords

ANTIINFECTIVE AGENT; DRUG DERIVATIVE; MINOCYCLINE; TIGECYCLINE;

ACINETOBACTER; ACINETOBACTER INFECTION; ARTICLE; DRUG EFFECT; FEMALE; HUMAN; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MULTIDRUG RESISTANCE;

ACINETOBACTER; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE;

ACINETOBACTER; ACINETOBACTER BAUMANNII; ACINETOBACTER LWOFFII; BACTERIA (MICROORGANISMS);

EID: 57349193502     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. CLSI, CLINICAL AND LABORATORY STANDARDS INSTITUTE. Performance standards for antimicrobial susceptibility testing. 16th Informational Supplement. M100-S16. Wayne, PA USA. (2006).
2. COELHO J.M., TURTON J.F., KAUFMANN M.E., GLOVER J., WOODFORD N., WARNER M., PALEPOU M., PIKE R., PITT T.L., PATEL B.C., LIVERMORE D.M. (2006). Occurence of carbapenem-resistant Acinetobacter baumannii clones at multiple hospitals in London and Southeast England. J. Clin. Microbiol. 44 (10), 3623-3627.
3. CORNAGLIA G., AKOVA M., AMICOSANTE G., CANTON R., CAUDA R., DOCQUIER J-D., EDELSTEIN M., FRERE J-M., FUZI M., GALLENI M., GIAMARELLOU H., GNIADKOWSKI M., KONCAN R., LIBISCH B., LUZZARO F., MIRIAGOU V., NAVARRO F., NORDMANN P., PAGANI L., PEIXE L., POIREL L., SOULI M., TACCONELLI E., VATOPOULOS A., ROSSOLINI G.M., ON BEHALF OF ESCMID STUDY GROUP FOR ANTIMICROBIAL RESISTANCE SURVEILLANCE (ESGARS). (2007). Metallo-beta-lactamases as emerging resistance determinants in Gram-negative pathogens:open issues. Int. J. Antimicrob. Agents. 29 (4), 380-388.
4. DIJKSHOORN L., NEMEC A., SEIFERT H. (2007). An increasing threat in hospitals: multidrug-resistant Acinetobacter baumanii. Nat. Rev. Microbiol. 5 (12), 939-951.
5. DIJKSHOORN L., AUCKEN H., GERNER-S MIDTH P., JANSSEN P., KAUFMANN M.E., GARAIZAR J., URSING J., PITT T.L. (1996). Comparison of outbreak and nonoutbreak Acinetobacter baumannii strains by genotypic and phenotypic methods. J. Clin. Microbiol. 34, 1519-1525.
6. FALAGAS M.E., KARVELI E.A., KELESIDIS I., KELESIDIS T. (2007). Community-acquired Acinetobacter infections. Eur. J. Clin. Microbiol. Infect. Dis. 26 (12), 857-868.
7. FALAGAS M.E., KASIAKOU S.F. (2005). Colistin: the revival of polymixins for the management of multidrug-resistant Gram-negative bacterial infections. Clin. Infect. Dis. 40 (9), 1333-1341.
8. FALAGAS M.E., KOLETSI P.K., BLIZIOTIS I.A. (2006). The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J. Med. Microbiol. 55 (12), 1619-1629.
9. GAYNES R., EDWARDS J.R., NATIONAL NOSOCOMIAL INFECTIONS SURVEILLANCE SYSTEM (2005). Overview of nosocomial infections caused by gram-negative bacilli. Clin. Infect. Dis. 41 (6), 848-854.
10. HALSTEAD D.C., ABID J., DOWZICKY M.J. (2007). Antimicrobial susceptibility among Acinetobacter calcoaceticus-baumannii complex and Enterobacteriaceae collected as part of the tigecycline evaluation and surveillance trial. J. Infect. 55 (1), 49-57.
11. HOBAN D.J., BOUCHILLON S.K., DOWZICKY M.J. (2007). Antimicrobial susceptibility of extended-spectrum beta-lactamase producers and multidrug-resistant Acinetobacter baumannii throughout the United States and comparative in vitro activity of tigecycline, a new glycylcycline antimicrobial. Diag. Microbiol. Infect. Dis. 57 (4), 423-428.
12. JAIN R., DANZIGER L.H. (2004). Multidrug-resistant Acinetobacter infections: An emerging challenge to clinicians. Ann. Pharmacother. 38 (9), 1449-1459.
13. JEONG S.H., BAE I.K., PARK K.O., AN Y.J., SOHN J.G., JANG S.J., SUNG K.H., YANG K.S., LEE K., YOUNG D. AND LEE S.H. (2006). Outbreaks of Imipenem-Resistant Acinetobacter baumannii producing carbapenemases in Korea. J. Microbiol. 44 (4), 423-431.
14. LIVERMORE D. (2005). Tigecycline: what is it and where should it be used? J. Antimicrob. Chemother. 56, 611-614.
15. LOTHOLARY O., FAGON J.Y., HOI A.B., SLAMA M.A., PIERRE J. GIRAL P., ROSENZWEIG R., GUTMANN L., SAFAR M., ACAR J. (1995). Nosocomial acquisition of multiresistant Acinetobacter baumannii: risk factors and prognosis. Clin. Infect. Dis. 20 (4), 790-796.
16. MASTERTON R., CRAVEN D., RELLO J., STRUELENS M., FRIMODT-MOLLER N., CHASTRE J., ORTQVIST A., COGNALIA G., LODE H., GIAMARELLOU H., BONTEN M.J., ERAKSOY H., DAVEY P. (2007). Hospital-acquired pneumonia guidelines in Europe: a review of their status and future development. J. Antimicrob. Chemother. 60 (2), 206-213.
17. MCGOWAN J.E. (2006). Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum. Am. J. Infect. Control. 34 (5 Suppl 1), 29-37.
18. MURRAY C.K., HOSPENTHAL D.R. (2005). Treatment of multidrug-resistant Acinetobacter. Curr. Opin. Infect. Dis. 18 (6), 502-506.
19. PELEG A.Y. (2007). Optimizing therapy for Acinetobacter baumannii. Semin. Respir. Crit. Care Med. 28 (6), 662-671.
20. PLAYFORD E.G., CRAIG D.C., IREDELL J.R. (2007). Carbapenem-resistant Acinetobacter baumannii in intensive care unit patients: risk factors for acquisition, infection and their consequences. J. Hosp. Infect. 65 (3), 204-211.
21. POIREL L., NORDMANN P. (2006). Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin. Microbiol. Infect. 12 (9), 826-836.
22. RICE L.B. (2006). Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa. Clin. Infect. Dis. 43 (Suppl 2), 100-105.
23. ROSE W.E., RYBAK M.J. (2006). Tigecycline: first of a new class of antimicrobial agents. Pharmacother. 26(8), 1099-1110.
24. ROSSOLINI G.M., MANTENGOLI E., DOCQUIER J.D., MUSMANNO R.A., RATNAM I., FRANKLIN C., SPELMAN D.W. (2007). In vitro activities of new and conventional antibiotics against multi-drug resistant Gram negative bacteria from patients in the intensive care units. Pathology. 39 (6), 586-588.
25. ROSSOLINI G.M., MANTENGOLI E., DOCQUIER J-D, MUSMANNO R.A., CORATZA G. (2007). Epidemiology of infections caused by multiresistant Gram-negatives: ESBLs, MBLs, panresistant strains. New Microbiologica. 30 (3), 332-339.
26. SEIFERT H., STEFANIK D., WISPLINGHOFF H. (2006). Comparative in vitro activities of tigecycline and 11 other antimicrobial agents 215 epidemiologically defined multidrug-resistant Acinetobacter baumannii isolates. J. Antimicrob. Chemother. 58 (5), 1099-1100.
27. SMOLYAKOV R., BORER A., RIESENBERG K., SCHLAEFFER F., ALKAN M., PORATH A., RIMAR D., ALMOG Y., GILAD Y. (2003). Nosocomial multi-drug resistant Acinetobacter baumannii infection: risk factors and outcome with ampicillin-sulbactam treatment. J. Hosp. Infect. 54 (1), 32-38.
28. TIENGRIM S., TRIBUDDHARAT C., THAMLIKITKUL V. (2006). In vitro activity of tigecycline against clinical isolates of multidrug-resistant Acinetobacter baumannii in Siriraj Hospital, Thailand. J. Med. Assoc. Thai. 89 (Suppl 5), 102-105.
29. TIMURKAYNAK F., CAN F., KURT AZAP O., DEMIRBILEK M., ARSLAN H., KARAMAN S.O. (2006). In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. Int. J. Antimicrob. Agents. 27 (3), 224-228.